Parker Truong, DO
Interventional Cardiology · Oklahoma City, OKNPI 1053409946
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 63.7% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $7,908 and has fallen 78.9% since, to $1,671 in 2025.
Across 390 payments — averaging $112.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$28K
- Philips North America LLC$5K
- Medtronic$2K
- Pfizer$904
- Shockwave Medical, Inc$782
- AstraZeneca$773
- plus $6K from 29 others
What the payments were for
- Consulting fees$21,50049%
- Speaking & faculty fees$3,5008%
- Travel & lodging$4,19410%
- Food & beverage$14,82934%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 90 | $28,071 |
| Philips North America LLC | 9 | $5,107 |
| Medtronic(2 entities) | 51 | $2,295 |
| Pfizer | 70 | $904 |
| Shockwave Medical, Inc | 11 | $782 |
| AstraZeneca | 10 | $773 |
| E.r. Squibb & Sons, L.L.C. | 30 | $768 |
| Boehringer Ingelheim | 6 | $748 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $698 |
| Terumo Medical Corporation | 7 | $595 |
| Amgen | 18 | $437 |
| Penumbra, Inc. | 3 | $430 |
| Johnson & Johnson | 14 | $396 |
| Esperion Therapeutics, Inc. | 2 | $249 |
| Biocompatibles, Inc. | 1 | $225 |
| Abbott | 3 | $174 |
| Amarin Pharma, Inc. | 4 | $159 |
| Avantec Vascular Corporation | 1 | $150 |
| Inari Medical, Inc. | 1 | $148 |
| Cathworks, Inc. | 1 | $136 |
| Surmodics, Inc. | 1 | $133 |
| Novartis | 6 | $130 |
| Merck | 7 | $110 |
| Cashflow Solutions, LLC | 3 | $89 |
| Novo Nordisk | 1 | $83 |
| Kestra Medical Technology Services, Inc. | 4 | $77 |
| Asahi Intecc USA, Inc. | 1 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Baxter Healthcare | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
| BTG International Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL VASCULAR INTERVENTION$6,061
- GENERAL - THERAPIES$4,993
- GlideLight$4,600
- ANGIOJET$3,853
- JARDIANCE$748
- FARXIGA$725
- GENERAL ATHERECTOMY$525
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$512
- ClosureFast$451
- Indigo System$430
- Micra$429
- AZUR$409
- ELIQUIS$362
- GENERAL EP$286
- NEXLIZET$249
- NEXLETOL$249
- VARITHENA$225
- FLOWTRIEVER CATHETER, S$148
- CT THROMBECTOMY SYSTEM KIT$148
- FFRangio$136
How this compares
$44,044 in reported general payments places this provider in the 85th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 464 | $477,203 |
| XareltoRivaroxaban | 108 | $91,513 |
| VascepaIcosapent Ethyl | 17 | $15,371 |
| EntrestoSacubitril/Valsartan | 15 | $11,835 |
| BrilintaTicagrelor | 11 | $9,558 |
| Metoprolol Succinate | 262 | $3,770 |
| Nebivolol Hcl | 34 | $3,308 |
| Ranolazine ErRanolazine | 22 | $3,192 |
| ClopidogrelClopidogrel Bisulfate | 208 | $2,899 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 18 | $2,486 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 313 | $2,443 |
| Atorvastatin Calcium | 229 | $2,408 |
| Potassium Chloride | 113 | $1,708 |
| Omega-3 Acid Ethyl Esters | 21 | $1,609 |
| Flecainide Acetate | 29 | $1,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $904 | $477,203464 claims |
| Johnson & JohnsonXarelto | $396 | $91,513108 claims |
| NovartisEntresto | $130 | $11,83515 claims |
| AstraZenecaBrilinta | $773 | $9,55811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Branislav SchifferdeckerOklahoma City$26K
- Mohit PahujaOklahoma City$21K
- Syed AliOklahoma City$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.